Here, we decided to extend this previous research by evaluating the effects of PARPi on the growth and cell cycle progression of breast cancer cells using three other well‐studied PARPi: olaparib and rucaparib, approved by FDA for the treatment of advances breast cancers with mutated‐BRCA1/2 [31], and ABT‐888 (veliparib), currently under evaluation in clinical trials [32]. This evidence concerns the gene BRCA1 and breast carcinoma.